In a couple of decades, the oncology community has become aware of rare cancers. They are the rare diseases of oncology; in Europe, a definition was proposed, a list was released, issues were highlighted. Some recommendations were put forward: healthcare should exploit clinical networking; research methodology should tackle low numbers, while a higher degree of uncertainty should be tolerated; shared clinical decision-making should be resorted to in order to manage such uncertainty1-6.